Look beyond rosacea redness with a full blood panel
Your membership includes inflammation, hormone, and metabolic markers in a single draw.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
At a glance
- Brimonidine gel (sold as Mirvaso) is a prescription topical that temporarily reduces the facial redness and flushing of rosacea.
- It works as a vasoconstrictor, narrowing small blood vessels so redness fades for several hours.
- It treats redness only and does not reduce the bumps or pustules of rosacea.
- Rebound redness, where flushing returns and can look worse, happens for some people.
- Evidence strength: Moderate, supported by randomized trials but with variable real-world tolerability.
What is brimonidine?
Brimonidine is a selective alpha-2 adrenergic receptor agonist, a drug that makes small blood vessels tighten. Applied as a facial gel, it constricts the widened surface vessels that make rosacea skin look flushed, so the face appears less red for a number of hours before the effect fades. In two randomized, vehicle-controlled studies, once-daily brimonidine gel reduced facial redness in a dose-dependent way, with a significant effect within about 30 minutes that lasted up to 12 hours.
What skin type is brimonidine best for?
Brimonidine suits people whose main rosacea concern is persistent facial redness or easy flushing rather than bumps. It can work across skin types, though very sensitive or reactive skin may be more likely to sting or react to it. It is best thought of as a redness treatment for specific occasions or daily cosmetic relief, not as a full rosacea regimen, and people with mostly inflammatory rosacea will need something else for the bumps.
What does brimonidine treat?
Brimonidine treats the persistent background redness of rosacea. In a GRADE systematic review, topical brimonidine had high-certainty evidence for reducing temporary persistent redness, the strongest rating among redness treatments. Importantly, it does nothing for papules, pustules, or visible broken vessels, and it does not change the underlying disease. It masks redness while it is active, so the redness returns once each application wears off.
How do you know if brimonidine can help your skin?
It is most likely to help if your rosacea shows up mainly as a flushed, red central face without many bumps, and if that redness bothers you enough to want short-term relief. A clinician can confirm that redness, not inflammation or visible vessels, is the main feature, since brimonidine will not help the others. Many prescribers suggest testing it on a small area first to see how your skin responds before daily use.
How do you use brimonidine?
Apply a small, pea-sized amount spread as a thin layer across the face once a day, avoiding the eyes and lips, on clean skin. Because the effect is cosmetic and temporary, some people use it only before events. Systemic absorption is low, which a pharmacokinetic study confirmed when it found blood levels well below those of the eye-drop form. Starting slowly helps you gauge both the benefit and any rebound.
What are the potential side effects of brimonidine?
The most discussed problem is rebound redness, where the face flushes again, sometimes more intensely, as the drug wears off, and this leads some people to stop using it. Other effects include burning or stinging, worsening flushing, itching, and skin irritation or contact dermatitis. Applying less product and spacing out use can reduce rebound for some. This is general information rather than medical advice, so follow your prescriber's guidance.
Evidence strength
Moderate: Randomized controlled trials clearly show brimonidine reduces rosacea redness for several hours, and review-level evidence rates that redness benefit highly. The reason the overall rating sits at moderate rather than strong is real-world tolerability, since the effect is temporary and a meaningful minority of users experience rebound redness or worsening flushing that limits how practical the drug is day to day. It also treats only one feature of rosacea.
References
- Fowler J, Jarratt M, Moore A, et al. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. British Journal of Dermatology. 2012;166(3):633-641. doi:10.1111/j.1365-2133.2011.10716.x
- van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. British Journal of Dermatology. 2019;181(1):65-79. doi:10.1111/bjd.17590
- Benkali K, Leoni M, Rony F, et al. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea. British Journal of Dermatology. 2014;171(1):162-169. doi:10.1111/bjd.12881
















